<?xml version='1.0' encoding='utf-8'?>
<!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:4dc17fff-a4b5-4990-a199-6cec09c385d3,g:616d6790-1169-4c4b-bc95-2884efae7446,d:3faf72acdbde470d86c2fb9f076dd8db--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sasb="http://www.sasb.org/xbrl/taxonomy/cor" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nvo="http://novonordisk.com/20201207" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvo-20201207</title></head><body><div style="display:none"><ix:header><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvo-20201207.xsd"/></ix:references><ix:resources><xbrli:context id="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="inspection"><xbrli:measure>nvo:inspection</xbrli:measure></xbrli:unit><xbrli:unit id="recall"><xbrli:measure>nvo:recall</xbrli:measure></xbrli:unit><xbrli:unit id="action"><xbrli:measure>nvo:action</xbrli:measure></xbrli:unit><xbrli:unit id="patient"><xbrli:measure>nvo:patient</xbrli:measure></xbrli:unit><xbrli:unit id="drug"><xbrli:measure>nvo:drug</xbrli:measure></xbrli:unit><xbrli:context id="ie3ec6a66056b4493bc812c7350e06fef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>nvo:employee</xbrli:measure></xbrli:unit><xbrli:context id="i968c0a667b554e33907874bc453b509b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id31b12b8986f4a30b2de9a172edade10_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i790d2f1d13374a9e847a599fe7feb055_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e8e6691e0bb4986b05e5d580c556b8d_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd955891bc144b3867af2266060a575_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sasb:GenderAxis">sasb:MaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia949065de7884a4580429c89c08cba34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sasb:GenderAxis">sasb:FemaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec4dd41003604a1591ba67856008d094_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sasb:GenderAxis">sasb:MaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab97778641ff426ba5a33ab7f5dec6a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sasb:GenderAxis">sasb:FemaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28c4b855a9e4071a39ca9c237eb15da_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sasb:GenderAxis">sasb:MaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd526452a3049e5bc94803580ecf1b8_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000353278</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sasb:GenderAxis">sasb:FemaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3faf72acdbde470d86c2fb9f076dd8db_32"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Table 1. Sustainability Disclosure Topics &amp; Accounting Metrics </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.629%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Topic</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Code</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounting Metric</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unit of Measure</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019 Disclosure</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notes/Questions</span></td></tr><tr style="height:45pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Safety of Clinical Trial Participants</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-210a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:ProcessesForObtainingInformedConsentOfIncentivesOfferedToParticipantsAndOfAnyClinicalTrialsTerminatedDueToFailureToFollowGoodClinicalPracticeStandardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMS01LTEtMS0xMTY_6dd17574-7378-47e5-802f-db3a3696c9cb" escape="true"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMS01LTEtMS0xMTY_8bb69854-886c-4269-9ba0-e6dedb55b787" escape="true"><div><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Every day, millions of people rely on the quality and safety of our products.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">All medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints received on marketed products. By monitoring quality and safety information on our products we can take due and appropriate actions to safeguard patient safety if needed.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">We have in place a Quality Management System to ensure that we adhere to international and local legislation and that safety information is handled in the same way no matter in which country the patient lives. </span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Our Global Safety team has a pharmacovigilance system in place ensuring that the necessary means for collection and notification of any safety data are in place.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prior to any clinical investigation of a new pharmaceutical product or medical device, a safety committee with members from all relevant functional areas is established. This committee will exist throughout the product or device’s life-cycle. It is a multi-disciplinary team providing assessments of safety data, for a pharmaceutical product or medical device in development or on the market.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Our Quality Management System includes the following process to ensure we continuously assess risks and act upon findings in a timely manner:  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt">Information about side effects, technical complaints and counterfeits are received from multiple sources, for example clinical trial participants, patients, healthcare professionals, partner companies, health authorities and literature</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt">This information is entered into our complaint database, and side effects are also transferred and evaluated in the Novo Nordisk safety database</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt">Regular analysis of data in the safety database is done to look for patterns associated with complaints, including side effects, such as new types or higher frequency of side effects.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt">In parallel, the health authorities independently review the information. This dual system for surveillance of data ensures optimal patient safety.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt">All relevant safety data from clinical trials, as well as safety data on marketed products, is presented to the safety committee on a regular basis. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt">The safety committee decides on any necessary actions and the safety committee chairperson ensures actions are communicated to the relevant Novo Nordisk business area(s) for implementation. Actions could include advice on how the medicine should be used, inclusion of new warnings in the package leaflet, or ultimately stopping the use of the product.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Further procedures ensure we can react promptly and adequately if one of our products on the market, or used in clinical trials, is suspected of being affected by a significant product defect, such as recalling affected products.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">We are committed to patient safety and want to make it easy for patients to get in contact with us, if they have a complaint or want to report a side effect. Therefore, we have established easily accessible online complaint reporting directions with contact information in local language.</span></div></ix:nonNumeric></ix:nonNumeric></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">https://www.novonordisk.com/sustainable-business/Reporting-and-transparency.html</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Section “Patient Safety”</span></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-210a.2</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="inspection" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="INF" name="sasb:FdaInspectionsRelatedToClinicalTrialManagementAndPharmacovigilance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMi01LTEtMS02Ng_bc9dd992-3d8b-4bd3-b980-6211d7c119af">0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social Performance &gt; Statement &amp; 9.6 Failed inspections</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-210a.3</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reporting Currency</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:221pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Access to Medicines</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-240a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:ActionsAndInitiativesToPromoteAccessToHealthCareProductsForPriorityDiseasesAndInPriorityCountriesAsDefinedByTheAccessToMedicineIndexTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfNC01LTEtMS0xNTQ_a2b6c713-c257-42bd-bb35-951cd3838202" escape="true">Our Access to Insulin Commitment<br/>Through our Access to Insulin Commitment we have set a ceiling price of USD 4.00 per 10 ml vial of human insulin offered to governments in 76 low - and middle-income countries and to humanitarian organisations.  <br/><br/>In 2019, the average price the insulin was sold at under the commitment was USD 2.9 per vial, equalling 12 cents per patient per day.1 An estimated 2.9 million people were treated with insulin under this commitment in 2019, of which approximately 200,000 people were reached through sales to humanitarian organisations.  <br/><br/>Beyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated additional 2.2 million people in 2019. From August 2020, we have set a new ceiling price of USD 3.00 per 10 ml vial of human insulin. <br/><br/>Changing Diabetes® in Children<br/>Established in 2009, our Changing Diabetes® in Children programme provides insulin free of charge to clinics caring for children with type 1 diabetes. The programme also supports healthcare capacity building in 14 of the world’s poorest countries.  <br/><br/>In 2019, we enrolled 2,819 additional children, and currently the programme has resulted in:  <br/><br/>-26, 500+ children and adolescents enrolled in the programme.<br/>-208 clinics established across Bangladesh, Cambodia, Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, India, Ivory Coast, Kenya, Myanmar, Senegal, Sudan, Tanzania and Uganda.  <br/>-1,8+ million vials of insulin (100 units) donated to programme clinics. <br/>-15,121 healthcare professionals receiving diabetes care training.  <br/>-With the launch of our Defeat Diabetes strategy in 2020, we expanded the programme to reach 100,000 children by 2030.</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under ""Access to Care"" section&gt; Our Access to Insulin Committment<br/><br/>https://www.novonordisk.com/sustainable-business/Reporting-and-transparency.html</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-240a.2</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Affordability &amp; Pricing</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-240b.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-240b.2</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Percentage (%)</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-240b.3</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Percentage (%)</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.629%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.195%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="5" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Drug Safety</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-250a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-250a.2</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-250a.3</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of recalls issued, total units recalled</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="recall" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="INF" name="sasb:ProductRecalls" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTEtNS0xLTEtNjY_f8ec8701-681b-4955-ab28-af83ee27e0c2">4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social Performance &gt; Statement &amp; 9.5 Product recalls</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-250a.4</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total amount of product accepted for takeback, reuse, or disposal</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Metric tons (t)</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-250a.5</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="action" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="INF" name="sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTMtNS0xLTEtMTEx_9ae31787-5570-4265-91fa-fa767b3de69f">0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social Performance &gt; Statement &amp; 9.6 Failed Inspections</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:116pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Counterfeit Drugs</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-260a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:MethodsAndTechnologiesUsedToMaintainTraceabilityOfProductsThroughoutTheDistributionChainTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTQtNS0xLTEtMTUw_c8f82607-a7d0-4f42-b3d9-33be99e7a307" escape="true">To ensure patient safety, we have been implementing a comprehensive anti-counterfeit programme. A cross functional Anti-Counterfeit Working Group, chaired by the head of our Customer Complaint Centre, ensures vigilant risk assessment and implementation of an Anti-Counterfeit Product strategy.   <br/><br/>We have an ongoing international collaboration with regulatory bodies, scientific and trade organisations, law enforcement agencies and other stakeholders to investigate counterfeit products and to influence legislation regarding new anti-counterfeit measures. Those found guilty of producing or/and distributing counterfeit Novo Nordisk products are given fines and/or custodial sentences. China, as a result of lobbying and official intervention, has increased the length of sentences for counterfeiting.<br/><br/>We are a member of the Pharmaceutical Security Institute (PSI), which on behalf of the approximately 30 largest pharmaceutical companies, collects information and coordinates investigations into counterfeit products worldwide.</ix:nonNumeric> <br/></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under ""Counterfeit Products"" section<br/><br/>https://www.novonordisk.com/sustainable-business/Reporting-and-transparency.html</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:144pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-260a.2</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:CounterfeitProductsProcessForAlertingCustomersAndBusinessPartnersOfPotentialOrKnownRisksTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTUtNS0xLTEtMTUw_7a4bbf45-e4f3-45b8-bec2-22f092d128b9" escape="true">At Novo Nordisk, we conduct regular reviews of risks through information exchange with external collaborators. The investigation of suspected counterfeit cases is reported via our affiliates or authorities. Monthly internal counterfeit surveillance reports are reviewed by key specialists and management.<br/><br/>Our Quality Management System identifies and investigates alleged occurrences of counterfeited Novo Nordisk products. In China, we work with local investigation firms to perform market searches to help health authorities track down and seize counterfeit products. Outside China, we conduct investigations of suspected counterfeit products based on risk analysis and take legal action against those involved in the counterfeiting of our products.  <br/><br/>Recognising that low awareness and under-reporting are known issues in many countries, we provide internal video training for our affiliates globally. <br/><br/>In China, our proactive approach including collaboration with and training of local authorities, and scouting for counterfeit products and reporting these to local authorities has enabled us to keep counterfeit products at a relatively lower level. Currently, the main products being counterfeited are NovoFine® in China and Norditropin® sold via the internet or in fitness centres.</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under ""Counterfeit Products"" section<br/><br/>https://www.novonordisk.com/sustainable-business/Reporting-and-transparency.html</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-260a.3</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ethical Marketing</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-270a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total amount of monetary losses as a result of legal proceedings associated with false marketing claims</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reporting Currency</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-270a.2</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Description of code of ethics governing promotion of off-label use of products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.629%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.195%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee Recruitment, Development &amp; Retention</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-330a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discussion of talent recruitment and retention efforts for scientists and research and development personnel</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-330a.2</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rate</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social Performance &gt; Statement &amp; 8.1 Employees</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The rate of turnover is measured as the number of employees, excluding temporary employees, who left the Group during the financial year divided by the average number of employees, excluding temporary employees. Employee Turnover in 2019 was 11.4%. </span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:45pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Supply Chain Management</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-430a.1</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent thirdparty audit programs for integrity of supply chain and ingredients</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Percentage (%)</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social Performance &gt; Statement &amp; 9.4 Supplier audits</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The number of supplier audits concluded by Novo Nordisk’s Corporate Quality function includes the number of responsible sourcing audits and quality audits conducted among suppliers. 27 responsible sourcing audits and 209 quality audits were conducted in 2019.<br/><br/>The number of audits concluded in 2019 decreased by 20% compared with 2018. The decrease in quality audits was due to the additional qualification audits in 2018 supporting, among others, the diabetes API project in the US. There were no critical findings related to the quality audits, but one critical finding was issued in connection with a responsible sourcing audit regarding working hours. An action plan with concrete deadlines has been agreed upon and a responsible sourcing re-audit is planned for 2020 to follow up on improvements.</span></td></tr><tr style="height:45pt"><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business Ethics</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-510a.1</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reporting Currency</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-510a.2</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Description of code of ethics governing interactions with health care professionals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:CodeOfEthicsGoverningInteractionsWithHealthCareProfessionalsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMjMtNS0xLTEtNzI_f88b2e8a-2360-43f5-ab5e-910caeb8266d" escape="true">Novo Nordisk’s responsibility to respect la- bour rights applies to our global operations as a global minimum standard of business conduct. In 2019, the Global Labour Code of Conduct was revitalised and reinforced to ensure alignment with Novo Nordisk’s Business Ethics Compliance Framework, which includes respect of human rights. The Code of Conduct describes expected global minimum labour rights requirements for Novo Nordisk employees including the principles concerning fundamental rights in the eight ILO Core Conventions and labour rights as stipulated in the International Bill of Human Rights. Minimum paid maternity leave is increased from 12 to 14 weeks globally and a right to paid paternity leave is introduced. Moreover, guidance to avoid forced and bonded labour/child labour and young workers is better described, the right to social security is affirmed, and life insurance for all employees is introduced. For more information see novonordisk.com.</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Our Business &gt; Social Performance &gt; Employees (Pg 26)</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-510a.2</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Description of code of ethics governing interactions with health care professionals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:CodeOfEthicsGoverningInteractionsWithHealthCareProfessionalsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMjQtNS0xLTEtNzI_8290e798-d2c7-417b-9cdd-a5f1004ee265" escape="true">In Novo Nordisk Business Ethics, Data Privacy and Human Rights is about acting with integrity and in compliance with the Novo Nordisk Way, the Business Ethics Code of Conduct as well as international and local standards for responsible business conduct.<br/>Training in Business Ethics is mandatory and a high priority. Annual Business Ethics training is required for all employees, includ- ing new hires. Business Ethics training is therefore a key element of the onboarding programmes. In 2019, 99% of all relevant employees completed and documented their training. This high level is attributed to the constant focus on and communication by senior management of the importance of business ethics compliance. In 2019, 34 business ethics reviews were completed with 87 findings, compared with 33 re- views with 113 findings in 2018. Based on the completed business ethics reviews, it is Group Internal Audit's assessment that the business ethics compliance level is sound. Management action plans and closure of findings progressed as planned, and there were no overdue Management actions or findings at the end of the year.<br/>During 2019 Novo Nordisk developed and approved its internal corporate require- ments on Data Privacy and Human Rights which is operationalised in the Novo Nordisk’s Business Ethics Code of Conduct. The requirements set out guidance and expectations to all employees. Furthermore, Data Privacy and Human Rights risks (‘risks to people’) were integrated into the Busi- ness Ethics risk methodology, as the basis for risk management in the Novo Nordisk global organisation as of 2020.</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Our Business &gt; Social Performance &gt; Business ethics, data privacy and human rights (Pg 27)</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Table 2. Activity Metrics</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.979%"><tr><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Code</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Activity Metric</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Category</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unit of Measure</span></td><td colspan="6" style="background-color:#dbdbdb;border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019 Amount</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notes/Questions</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-000.A</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of patients treated</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quantitative</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="6" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="patient" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sasb:PatientsTreatedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjNhMmMxNDA4NWFkODQ3ZTZhMjI3MmEzZDRmNTYxNTI4L3RhYmxlcmFuZ2U6M2EyYzE0MDg1YWQ4NDdlNmEyMjcyYTNkNGY1NjE1MjhfMS00LTEtMS05NA_b661576b-ede0-48bc-ab3f-3c78c9bb9b4e">30.0</ix:nonFraction> million</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social Performance &gt; Statement &amp; 7.1 Patients reached with Novo Nordisk diabetes products (estimate)</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HC-BP-000.B</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quantitative</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In portfolio : </span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="drug" contextRef="ie3ec6a66056b4493bc812c7350e06fef_I20191231" decimals="INF" name="sasb:DrugsInPortfolioNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjNhMmMxNDA4NWFkODQ3ZTZhMjI3MmEzZDRmNTYxNTI4L3RhYmxlcmFuZ2U6M2EyYzE0MDg1YWQ4NDdlNmEyMjcyYTNkNGY1NjE1MjhfMi01LTEtMS05Mg_17a8b6f0-1f50-40c0-ba1d-5357dcc7c826">2</ix:nonFraction></span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pipeline Overview (Pg 14)</span></td><td colspan="3" style="border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In R&amp;D</span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="drug" contextRef="ie3ec6a66056b4493bc812c7350e06fef_I20191231" decimals="INF" name="sasb:DrugsInResearchAndDevelopmentNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjNhMmMxNDA4NWFkODQ3ZTZhMjI3MmEzZDRmNTYxNTI4L3RhYmxlcmFuZ2U6M2EyYzE0MDg1YWQ4NDdlNmEyMjcyYTNkNGY1NjE1MjhfMy01LTEtMS05Mg_89b18e05-5629-4124-a7ce-965d90c2670d">18</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #dbdbdb;border-left:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3faf72acdbde470d86c2fb9f076dd8db_99"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><img src="nvo-20201207_g1.png" alt="nvo-20201207_g1.png" style="height:543px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#061861;font-family:'Arial',sans-serif;font-size:20pt;font-weight:400;line-height:120%">Patient Safety</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:ProcessesForObtainingInformedConsentOfIncentivesOfferedToParticipantsAndOfAnyClinicalTrialsTerminatedDueToFailureToFollowGoodClinicalPracticeStandardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl85OS9mcmFnOmQ1ZWZhYzk1YTE5YjQxMzRiY2JjNjk0ZGI4NTQ1ZTI3L3RleHRyZWdpb246ZDVlZmFjOTVhMTliNDEzNGJjYmM2OTRkYjg1NDVlMjdfMjc0ODc3OTA3ODkwNw_6dd17574-7378-47e5-802f-db3a3696c9cb" escape="true"><ix:nonNumeric contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" name="sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl85OS9mcmFnOmQ1ZWZhYzk1YTE5YjQxMzRiY2JjNjk0ZGI4NTQ1ZTI3L3RleHRyZWdpb246ZDVlZmFjOTVhMTliNDEzNGJjYmM2OTRkYjg1NDVlMjdfMjc0ODc3OTA3ODkwNw_8bb69854-886c-4269-9ba0-e6dedb55b787" escape="true"><div><span style="color:#061861;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Every day, millions of people rely on the quality and safety of our products.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints received on marketed products. By monitoring quality and safety information on our products we can take due and appropriate actions to safeguard patient safety if needed.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in place a Quality Management System to ensure that we adhere to international and local legislation and that safety information is handled in the same way no matter in which country the patient lives. </span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Global Safety team has a pharmacovigilance system in place ensuring that the necessary means for collection and notification of any safety data are in place.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to any clinical investigation of a new pharmaceutical product or medical device, a safety committee with members from all relevant functional areas is established. This committee will exist throughout the product or device’s life-cycle. It is a multi-disciplinary team providing assessments of safety data, for a pharmaceutical product or medical device in development or on the market.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Quality Management System includes the following process to ensure we continuously assess risks and act upon findings in a timely manner:  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Information about side effects, technical complaints and counterfeits are received from multiple sources, for example clinical trial participants, patients, healthcare professionals, partner companies, health authorities and literature</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">This information is entered into our complaint database, and side effects are also transferred and evaluated in the Novo Nordisk safety database</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regular analysis of data in the safety database is done to look for patterns associated with complaints, including side effects, such as new types or higher frequency of side effects.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In parallel, the health authorities independently review the information. This dual system for surveillance of data ensures optimal patient safety.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All relevant safety data from clinical trials, as well as safety data on marketed products, is presented to the safety committee on a regular basis. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The safety committee decides on any necessary actions and the safety committee chairperson ensures actions are communicated to the relevant Novo Nordisk business area(s) for implementation. Actions could include advice on how the medicine should be used, inclusion of new warnings in the package leaflet, or ultimately stopping the use of the product.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further procedures ensure we can react promptly and adequately if one of our products on the market, or used in clinical trials, is suspected of being affected by a significant product defect, such as recalling affected products.</span></div><div style="margin-bottom:9pt"><span style="color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to patient safety and want to make it easy for patients to get in contact with us, if they have a complaint or want to report a side effect. Therefore, we have established easily accessible online complaint reporting directions with contact information in local language.</span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3faf72acdbde470d86c2fb9f076dd8db_80"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#061861;font-family:'Lato Black',sans-serif;font-size:48pt;font-weight:400;line-height:120%">Statement of </span></div><div><span style="color:#061861;font-family:'Lato Black',sans-serif;font-size:48pt;font-weight:400;line-height:120%">social </span></div><div><span style="color:#061861;font-family:'Lato Black',sans-serif;font-size:48pt;font-weight:400;line-height:120%">performance</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for the year ended 31 December</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patients</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e3ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e3ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients reached with Novo Nordisk's diabetes care products (estimate in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients reached with Novo Nordisk's diabetes care products via the Access to Insulin Commitment (estimate in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Donations (DKK million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animals purchased for research</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,637</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,593</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,623</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employees (total)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="employee" contextRef="ie3ec6a66056b4493bc812c7350e06fef_I20191231" decimals="INF" format="ixt:numdotdecimal" name="sasb:EmployeesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfNy0yLTEtMS02MDg_32d7a5e4-7070-446e-b125-e9ecb74d3364">43,258</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="employee" contextRef="i968c0a667b554e33907874bc453b509b_I20181231" decimals="INF" format="ixt:numdotdecimal" name="sasb:EmployeesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfNy00LTEtMS02MTI_defac494-0328-4dc1-afe8-b8383e430247">43,202</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="employee" contextRef="id31b12b8986f4a30b2de9a172edade10_I20171231" decimals="INF" format="ixt:numdotdecimal" name="sasb:EmployeesNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfNy01LTEtMS02MTQ_1161a6a4-bcc5-412e-880d-f2d29aba618d">42,682</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee turnover</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="2" style="background-color:#c6e3ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#c6e3ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee engagement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#c6e3ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="2" name="sasb:EmployeeEngagementPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfOS0yLTEtMS02OTg_6ce7640c-5759-44fe-b9ee-f878e579cd21">91</ix:nonFraction> </span></td><td style="background-color:#c6e3ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i790d2f1d13374a9e847a599fe7feb055_D20180101-20181231" decimals="2" name="sasb:EmployeeEngagementPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfOS00LTEtMS03MDE_0e96be67-c961-4a7f-9440-31145dd82bb7">91</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e8e6691e0bb4986b05e5d580c556b8d_D20170101-20171231" decimals="2" name="sasb:EmployeeEngagementPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfOS01LTEtMS03MDE_7019cc11-7285-411a-93f3-c068e27f53a4">90</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gender in management (ratio men:women)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idcd955891bc144b3867af2266060a575_D20190101-20191231" decimals="2" name="sasb:EmployeesPercentageOfManagement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtMi0xLTEtNjE4L3RleHRyZWdpb246ZDBkYWRjMGZhMzkwNDQyOGEyNGE2YmJmN2M3MDY0M2ZfMjE5OTAyMzI1NTU2Mw_f002afd3-3593-4768-a930-78e7b34c48db">60</ix:nonFraction>:<ix:nonFraction unitRef="number" contextRef="ia949065de7884a4580429c89c08cba34_D20190101-20191231" decimals="2" name="sasb:EmployeesPercentageOfManagement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtMi0xLTEtNjE4L3RleHRyZWdpb246ZDBkYWRjMGZhMzkwNDQyOGEyNGE2YmJmN2M3MDY0M2ZfMjE5OTAyMzI1NTU2OQ_05b03b4e-57bb-4ef3-bda6-5b2c92f729d1">40</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec4dd41003604a1591ba67856008d094_D20180101-20181231" decimals="2" name="sasb:EmployeesPercentageOfManagement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNC0xLTEtNjYwL3RleHRyZWdpb246OGQ1M2EyOGZmOTM1NGEwMDhmNTdiYTE3OGEzNzI2MWJfMjE5OTAyMzI1NTU2Mw_a8f6d509-d2d7-406b-9e9b-58dce287140f">60</ix:nonFraction>:<ix:nonFraction unitRef="number" contextRef="iab97778641ff426ba5a33ab7f5dec6a6_D20180101-20181231" decimals="2" name="sasb:EmployeesPercentageOfManagement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNC0xLTEtNjYwL3RleHRyZWdpb246OGQ1M2EyOGZmOTM1NGEwMDhmNTdiYTE3OGEzNzI2MWJfMjE5OTAyMzI1NTU2OA_a5b23870-a14b-4d65-b92c-1100ca5f654c">40</ix:nonFraction></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie28c4b855a9e4071a39ca9c237eb15da_D20170101-20171231" decimals="2" name="sasb:EmployeesPercentageOfManagement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNS0xLTEtNjY4L3RleHRyZWdpb246NTJlODMxOTVkMDk0NDA0NGIyMWYwYzY2ODhhMTQ0NWZfMjE5OTAyMzI1NTU2Mw_ee8ab7b7-5467-4ce8-8711-6e945f597d66">60</ix:nonFraction>:<ix:nonFraction unitRef="number" contextRef="i5dd526452a3049e5bc94803580ecf1b8_D20170101-20171231" decimals="2" name="sasb:EmployeesPercentageOfManagement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNS0xLTEtNjY4L3RleHRyZWdpb246NTJlODMxOTVkMDk0NDA0NGIyMWYwYzY2ODhhMTQ0NWZfMjE5OTAyMzI1NTU2OA_252082c3-affb-4bee-ab5e-f74fc1e421d7">40</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Frequency of occupational accidents (number per million working hours)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Responsible business</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Relevant employees trained in business ethics</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="2" style="background-color:#c6e3ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#c6e3ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business ethics reviews</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilitations of the Novo Nordisk Way</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier audits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product recalls</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3faf72acdbde470d86c2fb9f076dd8db_86">9.5</a></span></div></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="recall" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="INF" name="sasb:ProductRecalls" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTctMi0xLTEtNDk3_f8ec8701-681b-4955-ab28-af83ee27e0c2">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="recall" contextRef="i790d2f1d13374a9e847a599fe7feb055_D20180101-20181231" decimals="INF" name="sasb:ProductRecalls" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTctNC0xLTEtNTA3_b2f5e2fd-b380-46a4-90c5-ff575b2b8edb">3</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="recall" contextRef="i5e8e6691e0bb4986b05e5d580c556b8d_D20170101-20171231" decimals="INF" name="sasb:ProductRecalls" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTctNS0xLTEtNTE0_23e5afc9-45f5-4bcb-87a4-22ed11273aed">6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Failed inspections</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3faf72acdbde470d86c2fb9f076dd8db_93">9.6</a></span></div></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="action" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="INF" name="sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTgtMi0xLTEtNTIx_9ae31787-5570-4265-91fa-fa767b3de69f">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="action" contextRef="i790d2f1d13374a9e847a599fe7feb055_D20180101-20181231" decimals="INF" name="sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTgtNC0xLTEtNTI4_fac135e6-0244-448b-a8d0-1aef8c8d7c24">0</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="action" contextRef="i5e8e6691e0bb4986b05e5d580c556b8d_D20170101-20171231" decimals="INF" name="sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTgtNS0xLTEtNTI4_0e17a074-9a14-4a40-9a5e-e6924f6c40cd">0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company trust (scale 0–100)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7</span></td><td colspan="3" style="background-color:#c6e3ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.2</span></td><td colspan="3" style="background-color:#c6e3ec;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total tax contribution (DKK million)</span></td><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8</span></td><td colspan="3" style="background-color:#c6e3ec;border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,527</span></td><td colspan="3" style="background-color:#c6e3ec;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825</span></td><td colspan="3" style="border-bottom:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. Scope of Access to Insulin Commitment expanded in 2019 to also include middle-income countries and selected organisations providing humanitarian relief.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i3faf72acdbde470d86c2fb9f076dd8db_86"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">9.5 Product recalls</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting policies</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of product recalls is recorded as the number of times Novo Nordisk has instituted a recall and includes recalls in connection with clinical trials. A recall can affect various countries.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novo Nordisk had <ix:nonFraction unitRef="recall" contextRef="i71c8f613116f4f1b89f6987eeccc967d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sasb:ProductRecalls" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84Ni9mcmFnOjI1MWM2ODQ0MDU1MDRlMWI4NGYzNzNiYTFjOTMxNDRlL3RleHRyZWdpb246MjUxYzY4NDQwNTUwNGUxYjg0ZjM3M2JhMWM5MzE0NGVfMjc0ODc3OTA3MjM5Mg_f8ec8701-681b-4955-ab28-af83ee27e0c2">four</ix:nonFraction> product recalls from the market in 2019, compared with <ix:nonFraction unitRef="recall" contextRef="i790d2f1d13374a9e847a599fe7feb055_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="sasb:ProductRecalls" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84Ni9mcmFnOjI1MWM2ODQ0MDU1MDRlMWI4NGYzNzNiYTFjOTMxNDRlL3RleHRyZWdpb246MjUxYzY4NDQwNTUwNGUxYjg0ZjM3M2JhMWM5MzE0NGVfMjc0ODc3OTA3MjQwMQ_b2f5e2fd-b380-46a4-90c5-ff575b2b8edb">three</ix:nonFraction> in 2018. As in 2018, none of the recalls were critical. Local health authorities were informed in all instances to ensure that distributors, pharmacies, doctors and patients received appropriate information.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i3faf72acdbde470d86c2fb9f076dd8db_93"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">9.6 Failed inspections</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting policies</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of failed inspections is measured in relation to the US Food &amp; Drug Administration (USFDA), the European Medicines Agency (EMA), Notified Body (TÜV SUD) and domestic authorities for strategic manufacturing sites. Failed inspections are defined as inspections where Warning Letters or EMA non-compliance letters related to GMP inspections are received, GMP/ISO certificates for strategic sites are lost, pre-approval inspections result in a Warning Letter, study conclusions are changed due to GCP/GLP inspection issues, or marketing or import authorisations are withdrawn due to inspection issues. Strategic sites are defined as the manufacturing sites in Brazil, China, Denmark, France and the US.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In 2019, as in 2018, there were no failed inspections among those resolved at year-end. During the year, 66 inspections were conducted compared with 75 in 2018. At year-end, 44 inspections were passed and 22 were unresolved, as final inspection reports had not been received or the final authority acceptance was pending, which is normal. Follow-up on unresolved inspections continues in 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><!--BEGIN IXBRL VIEWER EXTENSIONS--><script src="ixbrlviewer.js" type="text/javascript"></script><script type="application/x.ixbrl-viewer+json">{
 "concepts": {
  "sasb:ProcessesForObtainingInformedConsentOfIncentivesOfferedToParticipantsAndOfAnyClinicalTrialsTerminatedDueToFailureToFollowGoodClinicalPracticeStandardsTextBlock": {
   "labels": {
    "doc": {
     "en-us": "Description of processes for obtaining informed consent, of incentives offered to participants, and of any clinical trials terminated due to failure to follow good clinical practice standards"
    },
    "ns0": {
     "en-us": "HC-BP-210a.1b"
    },
    "std": {
     "en-us": "Processes For Obtaining Informed Consent, Of Incentives Offered To Participants, And Of Any Clinical Trials Terminated Due To Failure To Follow Good Clinical Practice Standards [Text Block]"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-210a.1b"
     ]
    ]
   ]
  },
  "sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlock": {
   "labels": {
    "doc": {
     "en-us": "Discussion of management process for ensuring quality and patient safety during clinical trials, including those conducted with third-party clinical research organizations (CROs)"
    },
    "ns0": {
     "en-us": "HC-BP-210a.1"
    },
    "std": {
     "en-us": "Management Process For Ensuring Quality And Patient Safety During Clinical Trials [Text Block]"
    },
    "ns1": {
     "en-us": "Management Process For Ensuring Quality And Patient Safety During Clinical Trials [Text Block]"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-210a.1"
     ]
    ]
   ]
  },
  "sasb:FdaInspectionsRelatedToClinicalTrialManagementAndPharmacovigilance": {
   "labels": {
    "std": {
     "en-us": "FDA Inspections Related To Clinical Trial Management And Pharmacovigilance"
    },
    "ns0": {
     "en-us": "HC-BP-210a.2"
    },
    "doc": {
     "en-us": "U.S. Food and Drug Administration (FDA) Sponsored Inspections related to clinical trial management and pharmacovigilance"
    },
    "ns1": {
     "en-us": "FDA Inspections Related To Clinical Trial Management And Pharmacovigilance"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-210a.2"
     ]
    ]
   ]
  },
  "sasb:ActionsAndInitiativesToPromoteAccessToHealthCareProductsForPriorityDiseasesAndInPriorityCountriesAsDefinedByTheAccessToMedicineIndexTextBlock": {
   "labels": {
    "std": {
     "en-us": "Actions And Initiatives To Promote Access To Health Care Products For Priority Diseases And In Priority Countries As Defined By The Access To Medicine Index [Text Block]"
    },
    "doc": {
     "en-us": "Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index"
    },
    "ns0": {
     "en-us": "HC-BP-240a.1a"
    },
    "ns1": {
     "en-us": "Actions And Initiatives To Promote Access To Health Care Products For Priority Diseases And In Priority Countries As Defined By The Access To Medicine Index [Text Block]"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-240a.1a"
     ]
    ]
   ]
  },
  "sasb:ProductRecalls": {
   "labels": {
    "ns0": {
     "en-us": "TR-CR-250a.2"
    },
    "doc": {
     "en-us": "Number of recalls"
    },
    "std": {
     "en-us": "Product Recalls"
    },
    "ns1": {
     "en-us": "Product Recalls"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "CG-AM-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "CG-TS-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "FB-AG-250a.3a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "FB-FR-250a.2"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "FB-MP-250a.3a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "FB-PF-250a.4a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "FB-RN-250a.2a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-250a.3a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-DR-250a.2"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-MS-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-AE-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-CP-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-EE-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-AP-250a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-AU-250a.3"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-CR-250a.2"
     ]
    ]
   ]
  },
  "sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices": {
   "labels": {
    "std": {
     "en-us": "FDA Enforcement Actions Taken In Response To Violations Of Current Good Manufacturing Practices"
    },
    "ns0": {
     "en-us": "HC-MS-250a.4"
    },
    "doc": {
     "en-us": "Number of U.S. Food and Drug Administration (FDA) enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP)"
    },
    "ns1": {
     "en-us": "FDA Enforcement Actions Taken In Response To Violations Of Current Good Manufacturing Practices"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-250a.5"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-MS-250a.4"
     ]
    ]
   ]
  },
  "sasb:MethodsAndTechnologiesUsedToMaintainTraceabilityOfProductsThroughoutTheDistributionChainTextBlock": {
   "labels": {
    "doc": {
     "en-us": "Discussion of methods and technologies used to maintain traceability of products throughout the distribution chain"
    },
    "ns0": {
     "en-us": "HC-MS-430a.2a"
    },
    "std": {
     "en-us": "Methods And Technologies Used To Maintain Traceability Of Products Throughout The Distribution Chain [Text Block]"
    },
    "ns1": {
     "en-us": "Methods And Technologies Used To Maintain Traceability Of Products Throughout The Distribution Chain [Text Block]"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-260a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-DI-260a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-MS-430a.2a"
     ]
    ]
   ]
  },
  "sasb:CounterfeitProductsProcessForAlertingCustomersAndBusinessPartnersOfPotentialOrKnownRisksTextBlock": {
   "labels": {
    "std": {
     "en-us": "Counterfeit Products, Process For Alerting Customers And Business Partners Of Potential Or Known Risks [Text Block]"
    },
    "doc": {
     "en-us": "Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products"
    },
    "ns0": {
     "en-us": "HC-DI-260a.3a"
    },
    "ns1": {
     "en-us": "Counterfeit Products, Process For Alerting Customers And Business Partners Of Potential Or Known Risks [Text Block]"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-260a.2a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-DI-260a.3a"
     ]
    ]
   ]
  },
  "sasb:CodeOfEthicsGoverningInteractionsWithHealthCareProfessionalsTextBlock": {
   "labels": {
    "std": {
     "en-us": "Code Of Ethics Governing Interactions With Health Care Professionals [Text Block]"
    },
    "doc": {
     "en-us": "Description of code of ethics governing interactions with health care professionals"
    },
    "ns0": {
     "en-us": "HC-MS-510a.2a"
    },
    "ns1": {
     "en-us": "Code Of Ethics Governing Interactions With Health Care Professionals [Text Block]"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-510a.2a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-MS-510a.2a"
     ]
    ]
   ]
  },
  "sasb:PatientsTreatedNumber": {
   "labels": {
    "ns0": {
     "en-us": "HC-BP-000.Aa"
    },
    "doc": {
     "en-us": "Number of patients treated"
    },
    "std": {
     "en-us": "Patients Treated, Number"
    },
    "ns1": {
     "en-us": "Patients Treated, Number"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-000.Aa"
     ]
    ]
   ]
  },
  "sasb:DrugsInPortfolioNumber": {
   "labels": {
    "std": {
     "en-us": "Drugs In Portfolio, Number"
    },
    "ns0": {
     "en-us": "HC-BP-000.Ba"
    },
    "doc": {
     "en-us": "Number of drugs in portfolio"
    },
    "ns1": {
     "en-us": "Drugs In Portfolio, Number"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-000.Ba"
     ]
    ]
   ]
  },
  "sasb:DrugsInResearchAndDevelopmentNumber": {
   "labels": {
    "std": {
     "en-us": "Drugs In Research And Development, Number"
    },
    "ns0": {
     "en-us": "HC-BP-000.Bb"
    },
    "doc": {
     "en-us": "Number of drugs in research and development (Phases 1-3)"
    },
    "ns1": {
     "en-us": "Drugs In Research And Development, Number"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "HC-BP-000.Bb"
     ]
    ]
   ]
  },
  "sasb:EmployeesNumber": {
   "labels": {
    "ns0": {
     "en-us": "TR-RO-000.Ca"
    },
    "std": {
     "en-us": "Employees, Number"
    },
    "doc": {
     "en-us": "Number of employees"
    },
    "ns1": {
     "en-us": "Employees, Number"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "EM-MM-000.B"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "EM-MM-000.Ba"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "FB-RN-000.B"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-AE-000.Ba"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-CP-000.Ca"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-EE-000.Ba"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "RT-IG-000.Ba"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "SV-AD-000.Da"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "SV-ED-000.D"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "SV-PS-000.A"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TC-ES-000.Ca"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-AF-000.C"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-AF-000.Ca"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-CL-000.C"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-MT-000.A"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-RA-000.Ea"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-RO-000.C"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TR-RO-000.Ca"
     ]
    ]
   ]
  },
  "sasb:EmployeeEngagementPercentage": {
   "labels": {
    "ns0": {
     "en-us": "TC-SI-330a.2a"
    },
    "std": {
     "en-us": "Employee Engagement, Percentage"
    },
    "doc": {
     "en-us": "Employee engagement as a percentage"
    },
    "ns1": {
     "en-us": "Employee Engagement, Percentage"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "CG-EC-330a.1a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "SV-PS-330a.3a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TC-IM-330a.2a"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TC-SI-330a.2a"
     ]
    ]
   ]
  },
  "sasb:MaleMember": {
   "labels": {
    "std": {
     "en-us": "Male [Member]"
    },
    "ns0": {
     "en-us": "Male [Member]"
    }
   }
  },
  "sasb:GenderAxis": {
   "labels": {
    "std": {
     "en-us": "Gender [Axis]"
    },
    "ns0": {
     "en-us": "Gender [Axis]"
    }
   },
   "d": "e"
  },
  "sasb:EmployeesPercentageOfManagement": {
   "labels": {
    "ns0": {
     "en-us": "TC-SI-330a.3"
    },
    "std": {
     "en-us": "Employees, Percentage Of Management"
    },
    "doc": {
     "en-us": "Percentage of management who are a particular race, ethnicity, or gender"
    },
    "ns1": {
     "en-us": "Employees, Percentage Of Management"
    }
   },
   "r": [
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "CG-EC-330a.3"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "CG-MR-330a.1"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "SV-AD-330a.1"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TC-HW-330a.1"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TC-IM-330a.3"
     ]
    ],
    [
     [
      "Publisher",
      "Sustainability Accounting Standards Board (SASB)"
     ],
     [
      "Name",
      "Sustainability Accounting Standard"
     ],
     [
      "IssueDate",
      "2018-10-01"
     ],
     [
      "Section",
      "TC-SI-330a.3"
     ]
    ]
   ]
  },
  "sasb:FemaleMember": {
   "labels": {
    "std": {
     "en-us": "Female [Member]"
    },
    "ns0": {
     "en-us": "Female [Member]"
    }
   }
  }
 },
 "languages": {
  "en-us": "English (US)"
 },
 "facts": {
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMS01LTEtMS0xMTY_6dd17574-7378-47e5-802f-db3a3696c9cb": {
   "v": "\u003Cdiv\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EEvery day, millions of people rely on the quality and safety of our products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv\u003E\u003Cspan\u003E\u003Cbr/\u003E\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EAll medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints received on marketed products. By monitoring quality and safety information on our products we can take due and appropriate actions to safeguard patient safety if needed.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EWe have in place a Quality Management System to ensure that we adhere to international and local legislation and that safety information is handled in the same way no matter in which country the patient lives. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EOur Global Safety team has a pharmacovigilance system in place ensuring that the necessary means for collection and notification of any safety data are in place.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EPrior to any clinical investigation of a new pharmaceutical product or medical device, a safety committee with members from all relevant functional areas is established. This committee will exist throughout the product or device\u2019s life-cycle. It is a multi-disciplinary team providing assessments of safety data, for a pharmaceutical product or medical device in development or on the market.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EOur Quality Management System includes the following process to ensure we continuously assess risks and act upon findings in a timely manner:  \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EInformation about side effects, technical complaints and counterfeits are received from multiple sources, for example clinical trial participants, patients, healthcare professionals, partner companies, health authorities and literature\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EThis information is entered into our complaint database, and side effects are also transferred and evaluated in the Novo Nordisk safety database\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003ERegular analysis of data in the safety database is done to look for patterns associated with complaints, including side effects, such as new types or higher frequency of side effects.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EIn parallel, the health authorities independently review the information. This dual system for surveillance of data ensures optimal patient safety.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EAll relevant safety data from clinical trials, as well as safety data on marketed products, is presented to the safety committee on a regular basis. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EThe safety committee decides on any necessary actions and the safety committee chairperson ensures actions are communicated to the relevant Novo Nordisk business area(s) for implementation. Actions could include advice on how the medicine should be used, inclusion of new warnings in the package leaflet, or ultimately stopping the use of the product.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EFurther procedures ensure we can react promptly and adequately if one of our products on the market, or used in clinical trials, is suspected of being affected by a significant product defect, such as recalling affected products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EWe are committed to patient safety and want to make it easy for patients to get in contact with us, if they have a complaint or want to report a side effect. Therefore, we have established easily accessible online complaint reporting directions with contact information in local language.\u003C/span\u003E\u003C/div\u003E",
   "a": {
    "c": "sasb:ProcessesForObtainingInformedConsentOfIncentivesOfferedToParticipantsAndOfAnyClinicalTrialsTerminatedDueToFailureToFollowGoodClinicalPracticeStandardsTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMS01LTEtMS0xMTY_8bb69854-886c-4269-9ba0-e6dedb55b787": {
   "v": "\u003Cdiv\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EEvery day, millions of people rely on the quality and safety of our products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv\u003E\u003Cspan\u003E\u003Cbr/\u003E\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EAll medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints received on marketed products. By monitoring quality and safety information on our products we can take due and appropriate actions to safeguard patient safety if needed.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EWe have in place a Quality Management System to ensure that we adhere to international and local legislation and that safety information is handled in the same way no matter in which country the patient lives. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EOur Global Safety team has a pharmacovigilance system in place ensuring that the necessary means for collection and notification of any safety data are in place.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EPrior to any clinical investigation of a new pharmaceutical product or medical device, a safety committee with members from all relevant functional areas is established. This committee will exist throughout the product or device\u2019s life-cycle. It is a multi-disciplinary team providing assessments of safety data, for a pharmaceutical product or medical device in development or on the market.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EOur Quality Management System includes the following process to ensure we continuously assess risks and act upon findings in a timely manner:  \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EInformation about side effects, technical complaints and counterfeits are received from multiple sources, for example clinical trial participants, patients, healthcare professionals, partner companies, health authorities and literature\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EThis information is entered into our complaint database, and side effects are also transferred and evaluated in the Novo Nordisk safety database\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003ERegular analysis of data in the safety database is done to look for patterns associated with complaints, including side effects, such as new types or higher frequency of side effects.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EIn parallel, the health authorities independently review the information. This dual system for surveillance of data ensures optimal patient safety.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EAll relevant safety data from clinical trials, as well as safety data on marketed products, is presented to the safety committee on a regular basis. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:15.55pt\"\u003EThe safety committee decides on any necessary actions and the safety committee chairperson ensures actions are communicated to the relevant Novo Nordisk business area(s) for implementation. Actions could include advice on how the medicine should be used, inclusion of new warnings in the package leaflet, or ultimately stopping the use of the product.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EFurther procedures ensure we can react promptly and adequately if one of our products on the market, or used in clinical trials, is suspected of being affected by a significant product defect, such as recalling affected products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%\"\u003EWe are committed to patient safety and want to make it easy for patients to get in contact with us, if they have a complaint or want to report a side effect. Therefore, we have established easily accessible online complaint reporting directions with contact information in local language.\u003C/span\u003E\u003C/div\u003E",
   "a": {
    "c": "sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMi01LTEtMS02Ng_bc9dd992-3d8b-4bd3-b980-6211d7c119af": {
   "v": "0",
   "a": {
    "c": "sasb:FdaInspectionsRelatedToClinicalTrialManagementAndPharmacovigilance",
    "e": "e:0000353278",
    "u": "nvo:inspection",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfNC01LTEtMS0xNTQ_a2b6c713-c257-42bd-bb35-951cd3838202": {
   "v": "Our Access to Insulin Commitment\u003Cbr/\u003EThrough our Access to Insulin Commitment we have set a ceiling price of USD 4.00 per 10 ml vial of human insulin offered to governments in 76 low - and middle-income countries and to humanitarian organisations.  \u003Cbr/\u003E\u003Cbr/\u003EIn 2019, the average price the insulin was sold at under the commitment was USD 2.9 per vial, equalling 12 cents per patient per day.1 An estimated 2.9 million people were treated with insulin under this commitment in 2019, of which approximately 200,000 people were reached through sales to humanitarian organisations.  \u003Cbr/\u003E\u003Cbr/\u003EBeyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated additional 2.2 million people in 2019. From August 2020, we have set a new ceiling price of USD 3.00 per 10 ml vial of human insulin. \u003Cbr/\u003E\u003Cbr/\u003EChanging Diabetes\u00ae in Children\u003Cbr/\u003EEstablished in 2009, our Changing Diabetes\u00ae in Children programme provides insulin free of charge to clinics caring for children with type 1 diabetes. The programme also supports healthcare capacity building in 14 of the world\u2019s poorest countries.  \u003Cbr/\u003E\u003Cbr/\u003EIn 2019, we enrolled 2,819 additional children, and currently the programme has resulted in:  \u003Cbr/\u003E\u003Cbr/\u003E-26, 500+ children and adolescents enrolled in the programme.\u003Cbr/\u003E-208 clinics established across Bangladesh, Cambodia, Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, India, Ivory Coast, Kenya, Myanmar, Senegal, Sudan, Tanzania and Uganda.  \u003Cbr/\u003E-1,8+ million vials of insulin (100 units) donated to programme clinics. \u003Cbr/\u003E-15,121 healthcare professionals receiving diabetes care training.  \u003Cbr/\u003E-With the launch of our Defeat Diabetes strategy in 2020, we expanded the programme to reach 100,000 children by 2030.",
   "a": {
    "c": "sasb:ActionsAndInitiativesToPromoteAccessToHealthCareProductsForPriorityDiseasesAndInPriorityCountriesAsDefinedByTheAccessToMedicineIndexTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTEtNS0xLTEtNjY_f8ec8701-681b-4955-ab28-af83ee27e0c2": {
   "v": "4",
   "a": {
    "c": "sasb:ProductRecalls",
    "e": "e:0000353278",
    "u": "nvo:recall",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTMtNS0xLTEtMTEx_9ae31787-5570-4265-91fa-fa767b3de69f": {
   "v": "0",
   "a": {
    "c": "sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices",
    "e": "e:0000353278",
    "u": "nvo:action",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTQtNS0xLTEtMTUw_c8f82607-a7d0-4f42-b3d9-33be99e7a307": {
   "v": "To ensure patient safety, we have been implementing a comprehensive anti-counterfeit programme. A cross functional Anti-Counterfeit Working Group, chaired by the head of our Customer Complaint Centre, ensures vigilant risk assessment and implementation of an Anti-Counterfeit Product strategy.   \u003Cbr/\u003E\u003Cbr/\u003EWe have an ongoing international collaboration with regulatory bodies, scientific and trade organisations, law enforcement agencies and other stakeholders to investigate counterfeit products and to influence legislation regarding new anti-counterfeit measures. Those found guilty of producing or/and distributing counterfeit Novo Nordisk products are given fines and/or custodial sentences. China, as a result of lobbying and official intervention, has increased the length of sentences for counterfeiting.\u003Cbr/\u003E\u003Cbr/\u003EWe are a member of the Pharmaceutical Security Institute (PSI), which on behalf of the approximately 30 largest pharmaceutical companies, collects information and coordinates investigations into counterfeit products worldwide.",
   "a": {
    "c": "sasb:MethodsAndTechnologiesUsedToMaintainTraceabilityOfProductsThroughoutTheDistributionChainTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMTUtNS0xLTEtMTUw_7a4bbf45-e4f3-45b8-bec2-22f092d128b9": {
   "v": "At Novo Nordisk, we conduct regular reviews of risks through information exchange with external collaborators. The investigation of suspected counterfeit cases is reported via our affiliates or authorities. Monthly internal counterfeit surveillance reports are reviewed by key specialists and management.\u003Cbr/\u003E\u003Cbr/\u003EOur Quality Management System identifies and investigates alleged occurrences of counterfeited Novo Nordisk products. In China, we work with local investigation firms to perform market searches to help health authorities track down and seize counterfeit products. Outside China, we conduct investigations of suspected counterfeit products based on risk analysis and take legal action against those involved in the counterfeiting of our products.  \u003Cbr/\u003E\u003Cbr/\u003ERecognising that low awareness and under-reporting are known issues in many countries, we provide internal video training for our affiliates globally. \u003Cbr/\u003E\u003Cbr/\u003EIn China, our proactive approach including collaboration with and training of local authorities, and scouting for counterfeit products and reporting these to local authorities has enabled us to keep counterfeit products at a relatively lower level. Currently, the main products being counterfeited are NovoFine\u00ae in China and Norditropin\u00ae sold via the internet or in fitness centres.",
   "a": {
    "c": "sasb:CounterfeitProductsProcessForAlertingCustomersAndBusinessPartnersOfPotentialOrKnownRisksTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMjMtNS0xLTEtNzI_f88b2e8a-2360-43f5-ab5e-910caeb8266d": {
   "v": "Novo Nordisk\u2019s responsibility to respect la- bour rights applies to our global operations as a global minimum standard of business conduct. In 2019, the Global Labour Code of Conduct was revitalised and reinforced to ensure alignment with Novo Nordisk\u2019s Business Ethics Compliance Framework, which includes respect of human rights. The Code of Conduct describes expected global minimum labour rights requirements for Novo Nordisk employees including the principles concerning fundamental rights in the eight ILO Core Conventions and labour rights as stipulated in the International Bill of Human Rights. Minimum paid maternity leave is increased from 12 to 14 weeks globally and a right to paid paternity leave is introduced. Moreover, guidance to avoid forced and bonded labour/child labour and young workers is better described, the right to social security is affirmed, and life insurance for all employees is introduced. For more information see novonordisk.com.",
   "a": {
    "c": "sasb:CodeOfEthicsGoverningInteractionsWithHealthCareProfessionalsTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjI1NTg1ZTg5ODEzOTRmZmM5MjhmZWRmMmM1OTYzNGIwL3RhYmxlcmFuZ2U6MjU1ODVlODk4MTM5NGZmYzkyOGZlZGYyYzU5NjM0YjBfMjQtNS0xLTEtNzI_8290e798-d2c7-417b-9cdd-a5f1004ee265": {
   "v": "In Novo Nordisk Business Ethics, Data Privacy and Human Rights is about acting with integrity and in compliance with the Novo Nordisk Way, the Business Ethics Code of Conduct as well as international and local standards for responsible business conduct.\u003Cbr/\u003ETraining in Business Ethics is mandatory and a high priority. Annual Business Ethics training is required for all employees, includ- ing new hires. Business Ethics training is therefore a key element of the onboarding programmes. In 2019, 99% of all relevant employees completed and documented their training. This high level is attributed to the constant focus on and communication by senior management of the importance of business ethics compliance. In 2019, 34 business ethics reviews were completed with 87 findings, compared with 33 re- views with 113 findings in 2018. Based on the completed business ethics reviews, it is Group Internal Audit's assessment that the business ethics compliance level is sound. Management action plans and closure of findings progressed as planned, and there were no overdue Management actions or findings at the end of the year.\u003Cbr/\u003EDuring 2019 Novo Nordisk developed and approved its internal corporate require- ments on Data Privacy and Human Rights which is operationalised in the Novo Nordisk\u2019s Business Ethics Code of Conduct. The requirements set out guidance and expectations to all employees. Furthermore, Data Privacy and Human Rights risks (\u2018risks to people\u2019) were integrated into the Busi- ness Ethics risk methodology, as the basis for risk management in the Novo Nordisk global organisation as of 2020.",
   "a": {
    "c": "sasb:CodeOfEthicsGoverningInteractionsWithHealthCareProfessionalsTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjNhMmMxNDA4NWFkODQ3ZTZhMjI3MmEzZDRmNTYxNTI4L3RhYmxlcmFuZ2U6M2EyYzE0MDg1YWQ4NDdlNmEyMjcyYTNkNGY1NjE1MjhfMS00LTEtMS05NA_b661576b-ede0-48bc-ab3f-3c78c9bb9b4e": {
   "v": "30000000",
   "a": {
    "c": "sasb:PatientsTreatedNumber",
    "e": "e:0000353278",
    "u": "nvo:patient",
    "p": "2019-01-01/2020-01-01"
   },
   "f": "ixt:numdotdecimal",
   "d": -5
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjNhMmMxNDA4NWFkODQ3ZTZhMjI3MmEzZDRmNTYxNTI4L3RhYmxlcmFuZ2U6M2EyYzE0MDg1YWQ4NDdlNmEyMjcyYTNkNGY1NjE1MjhfMi01LTEtMS05Mg_17a8b6f0-1f50-40c0-ba1d-5357dcc7c826": {
   "v": "2",
   "a": {
    "c": "sasb:DrugsInPortfolioNumber",
    "e": "e:0000353278",
    "u": "nvo:drug",
    "p": "2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl8zMi9mcmFnOjhkMmFlNjNlMGUwMjQ0MTdiZDUwYzVhMmZmNTA4NGI2L3RhYmxlOjNhMmMxNDA4NWFkODQ3ZTZhMjI3MmEzZDRmNTYxNTI4L3RhYmxlcmFuZ2U6M2EyYzE0MDg1YWQ4NDdlNmEyMjcyYTNkNGY1NjE1MjhfMy01LTEtMS05Mg_89b18e05-5629-4124-a7ce-965d90c2670d": {
   "v": "18",
   "a": {
    "c": "sasb:DrugsInResearchAndDevelopmentNumber",
    "e": "e:0000353278",
    "u": "nvo:drug",
    "p": "2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl85OS9mcmFnOmQ1ZWZhYzk1YTE5YjQxMzRiY2JjNjk0ZGI4NTQ1ZTI3L3RleHRyZWdpb246ZDVlZmFjOTVhMTliNDEzNGJjYmM2OTRkYjg1NDVlMjdfMjc0ODc3OTA3ODkwNw_6dd17574-7378-47e5-802f-db3a3696c9cb": {
   "v": "\u003Cdiv\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%\"\u003EEvery day, millions of people rely on the quality and safety of our products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv\u003E\u003Cspan\u003E\u003Cbr/\u003E\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EAll medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints received on marketed products. By monitoring quality and safety information on our products we can take due and appropriate actions to safeguard patient safety if needed.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EWe have in place a Quality Management System to ensure that we adhere to international and local legislation and that safety information is handled in the same way no matter in which country the patient lives. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EOur Global Safety team has a pharmacovigilance system in place ensuring that the necessary means for collection and notification of any safety data are in place.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EPrior to any clinical investigation of a new pharmaceutical product or medical device, a safety committee with members from all relevant functional areas is established. This committee will exist throughout the product or device\u2019s life-cycle. It is a multi-disciplinary team providing assessments of safety data, for a pharmaceutical product or medical device in development or on the market.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EOur Quality Management System includes the following process to ensure we continuously assess risks and act upon findings in a timely manner:  \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EInformation about side effects, technical complaints and counterfeits are received from multiple sources, for example clinical trial participants, patients, healthcare professionals, partner companies, health authorities and literature\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EThis information is entered into our complaint database, and side effects are also transferred and evaluated in the Novo Nordisk safety database\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003ERegular analysis of data in the safety database is done to look for patterns associated with complaints, including side effects, such as new types or higher frequency of side effects.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EIn parallel, the health authorities independently review the information. This dual system for surveillance of data ensures optimal patient safety.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EAll relevant safety data from clinical trials, as well as safety data on marketed products, is presented to the safety committee on a regular basis. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EThe safety committee decides on any necessary actions and the safety committee chairperson ensures actions are communicated to the relevant Novo Nordisk business area(s) for implementation. Actions could include advice on how the medicine should be used, inclusion of new warnings in the package leaflet, or ultimately stopping the use of the product.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EFurther procedures ensure we can react promptly and adequately if one of our products on the market, or used in clinical trials, is suspected of being affected by a significant product defect, such as recalling affected products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EWe are committed to patient safety and want to make it easy for patients to get in contact with us, if they have a complaint or want to report a side effect. Therefore, we have established easily accessible online complaint reporting directions with contact information in local language.\u003C/span\u003E\u003C/div\u003E",
   "a": {
    "c": "sasb:ProcessesForObtainingInformedConsentOfIncentivesOfferedToParticipantsAndOfAnyClinicalTrialsTerminatedDueToFailureToFollowGoodClinicalPracticeStandardsTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl85OS9mcmFnOmQ1ZWZhYzk1YTE5YjQxMzRiY2JjNjk0ZGI4NTQ1ZTI3L3RleHRyZWdpb246ZDVlZmFjOTVhMTliNDEzNGJjYmM2OTRkYjg1NDVlMjdfMjc0ODc3OTA3ODkwNw_8bb69854-886c-4269-9ba0-e6dedb55b787": {
   "v": "\u003Cdiv\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%\"\u003EEvery day, millions of people rely on the quality and safety of our products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv\u003E\u003Cspan\u003E\u003Cbr/\u003E\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EAll medicines have potential side effects as well as benefits. We routinely monitor the safety and quality of all our products. This includes review of safety data from clinical studies and review of side effects and technical complaints received on marketed products. By monitoring quality and safety information on our products we can take due and appropriate actions to safeguard patient safety if needed.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EWe have in place a Quality Management System to ensure that we adhere to international and local legislation and that safety information is handled in the same way no matter in which country the patient lives. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EOur Global Safety team has a pharmacovigilance system in place ensuring that the necessary means for collection and notification of any safety data are in place.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EPrior to any clinical investigation of a new pharmaceutical product or medical device, a safety committee with members from all relevant functional areas is established. This committee will exist throughout the product or device\u2019s life-cycle. It is a multi-disciplinary team providing assessments of safety data, for a pharmaceutical product or medical device in development or on the market.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EOur Quality Management System includes the following process to ensure we continuously assess risks and act upon findings in a timely manner:  \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EInformation about side effects, technical complaints and counterfeits are received from multiple sources, for example clinical trial participants, patients, healthcare professionals, partner companies, health authorities and literature\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EThis information is entered into our complaint database, and side effects are also transferred and evaluated in the Novo Nordisk safety database\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003ERegular analysis of data in the safety database is done to look for patterns associated with complaints, including side effects, such as new types or higher frequency of side effects.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EIn parallel, the health authorities independently review the information. This dual system for surveillance of data ensures optimal patient safety.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EAll relevant safety data from clinical trials, as well as safety data on marketed products, is presented to the safety committee on a regular basis. \u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt;padding-left:36pt;text-indent:-18pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003E\u2022\u003C/span\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt\"\u003EThe safety committee decides on any necessary actions and the safety committee chairperson ensures actions are communicated to the relevant Novo Nordisk business area(s) for implementation. Actions could include advice on how the medicine should be used, inclusion of new warnings in the package leaflet, or ultimately stopping the use of the product.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EFurther procedures ensure we can react promptly and adequately if one of our products on the market, or used in clinical trials, is suspected of being affected by a significant product defect, such as recalling affected products.\u003C/span\u003E\u003C/div\u003E\u003Cdiv style=\"margin-bottom:9pt\"\u003E\u003Cspan style=\"color:#061861;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%\"\u003EWe are committed to patient safety and want to make it easy for patients to get in contact with us, if they have a complaint or want to report a side effect. Therefore, we have established easily accessible online complaint reporting directions with contact information in local language.\u003C/span\u003E\u003C/div\u003E",
   "a": {
    "c": "sasb:ManagementProcessForEnsuringQualityAndPatientSafetyDuringClinicalTrialsTextBlock",
    "e": "e:0000353278",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfNy0yLTEtMS02MDg_32d7a5e4-7070-446e-b125-e9ecb74d3364": {
   "v": "43258",
   "a": {
    "c": "sasb:EmployeesNumber",
    "e": "e:0000353278",
    "u": "nvo:employee",
    "p": "2020-01-01"
   },
   "f": "ixt:numdotdecimal"
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfNy00LTEtMS02MTI_defac494-0328-4dc1-afe8-b8383e430247": {
   "v": "43202",
   "a": {
    "c": "sasb:EmployeesNumber",
    "e": "e:0000353278",
    "u": "nvo:employee",
    "p": "2019-01-01"
   },
   "f": "ixt:numdotdecimal"
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfNy01LTEtMS02MTQ_1161a6a4-bcc5-412e-880d-f2d29aba618d": {
   "v": "42682",
   "a": {
    "c": "sasb:EmployeesNumber",
    "e": "e:0000353278",
    "u": "nvo:employee",
    "p": "2018-01-01"
   },
   "f": "ixt:numdotdecimal"
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfOS0yLTEtMS02OTg_6ce7640c-5759-44fe-b9ee-f878e579cd21": {
   "v": "0.91",
   "a": {
    "c": "sasb:EmployeeEngagementPercentage",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "p": "2019-01-01/2020-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfOS00LTEtMS03MDE_0e96be67-c961-4a7f-9440-31145dd82bb7": {
   "v": "0.91",
   "a": {
    "c": "sasb:EmployeeEngagementPercentage",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "p": "2018-01-01/2019-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfOS01LTEtMS03MDE_7019cc11-7285-411a-93f3-c068e27f53a4": {
   "v": "0.90",
   "a": {
    "c": "sasb:EmployeeEngagementPercentage",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "p": "2017-01-01/2018-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtMi0xLTEtNjE4L3RleHRyZWdpb246ZDBkYWRjMGZhMzkwNDQyOGEyNGE2YmJmN2M3MDY0M2ZfMjE5OTAyMzI1NTU2Mw_f002afd3-3593-4768-a930-78e7b34c48db": {
   "v": "0.60",
   "a": {
    "c": "sasb:EmployeesPercentageOfManagement",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "sasb:GenderAxis": "sasb:MaleMember",
    "p": "2019-01-01/2020-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtMi0xLTEtNjE4L3RleHRyZWdpb246ZDBkYWRjMGZhMzkwNDQyOGEyNGE2YmJmN2M3MDY0M2ZfMjE5OTAyMzI1NTU2OQ_05b03b4e-57bb-4ef3-bda6-5b2c92f729d1": {
   "v": "0.40",
   "a": {
    "c": "sasb:EmployeesPercentageOfManagement",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "sasb:GenderAxis": "sasb:FemaleMember",
    "p": "2019-01-01/2020-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNC0xLTEtNjYwL3RleHRyZWdpb246OGQ1M2EyOGZmOTM1NGEwMDhmNTdiYTE3OGEzNzI2MWJfMjE5OTAyMzI1NTU2Mw_a8f6d509-d2d7-406b-9e9b-58dce287140f": {
   "v": "0.60",
   "a": {
    "c": "sasb:EmployeesPercentageOfManagement",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "sasb:GenderAxis": "sasb:MaleMember",
    "p": "2018-01-01/2019-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNC0xLTEtNjYwL3RleHRyZWdpb246OGQ1M2EyOGZmOTM1NGEwMDhmNTdiYTE3OGEzNzI2MWJfMjE5OTAyMzI1NTU2OA_a5b23870-a14b-4d65-b92c-1100ca5f654c": {
   "v": "0.40",
   "a": {
    "c": "sasb:EmployeesPercentageOfManagement",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "sasb:GenderAxis": "sasb:FemaleMember",
    "p": "2018-01-01/2019-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNS0xLTEtNjY4L3RleHRyZWdpb246NTJlODMxOTVkMDk0NDA0NGIyMWYwYzY2ODhhMTQ0NWZfMjE5OTAyMzI1NTU2Mw_ee8ab7b7-5467-4ce8-8711-6e945f597d66": {
   "v": "0.60",
   "a": {
    "c": "sasb:EmployeesPercentageOfManagement",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "sasb:GenderAxis": "sasb:MaleMember",
    "p": "2017-01-01/2018-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTAtNS0xLTEtNjY4L3RleHRyZWdpb246NTJlODMxOTVkMDk0NDA0NGIyMWYwYzY2ODhhMTQ0NWZfMjE5OTAyMzI1NTU2OA_252082c3-affb-4bee-ab5e-f74fc1e421d7": {
   "v": "0.40",
   "a": {
    "c": "sasb:EmployeesPercentageOfManagement",
    "e": "e:0000353278",
    "u": "xbrli:pure",
    "sasb:GenderAxis": "sasb:FemaleMember",
    "p": "2017-01-01/2018-01-01"
   },
   "d": 2
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTctMi0xLTEtNDk3_f8ec8701-681b-4955-ab28-af83ee27e0c2": {
   "v": "4",
   "a": {
    "c": "sasb:ProductRecalls",
    "e": "e:0000353278",
    "u": "nvo:recall",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTctNC0xLTEtNTA3_b2f5e2fd-b380-46a4-90c5-ff575b2b8edb": {
   "v": "3",
   "a": {
    "c": "sasb:ProductRecalls",
    "e": "e:0000353278",
    "u": "nvo:recall",
    "p": "2018-01-01/2019-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTctNS0xLTEtNTE0_23e5afc9-45f5-4bcb-87a4-22ed11273aed": {
   "v": "6",
   "a": {
    "c": "sasb:ProductRecalls",
    "e": "e:0000353278",
    "u": "nvo:recall",
    "p": "2017-01-01/2018-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTgtMi0xLTEtNTIx_9ae31787-5570-4265-91fa-fa767b3de69f": {
   "v": "0",
   "a": {
    "c": "sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices",
    "e": "e:0000353278",
    "u": "nvo:action",
    "p": "2019-01-01/2020-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTgtNC0xLTEtNTI4_fac135e6-0244-448b-a8d0-1aef8c8d7c24": {
   "v": "0",
   "a": {
    "c": "sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices",
    "e": "e:0000353278",
    "u": "nvo:action",
    "p": "2018-01-01/2019-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84MC9mcmFnOmY2Y2EyZjZjNWVkMTQ2NmVhYTYxNDhjMWZkZjVlZjkyL3RhYmxlOmNkNjJiNmE1ZTU2NTQ3ZGQ5MThlMGE1MDEyMWM1ODJmL3RhYmxlcmFuZ2U6Y2Q2MmI2YTVlNTY1NDdkZDkxOGUwYTUwMTIxYzU4MmZfMTgtNS0xLTEtNTI4_0e17a074-9a14-4a40-9a5e-e6924f6c40cd": {
   "v": "0",
   "a": {
    "c": "sasb:FdaEnforcementActionsTakenInResponseToViolationsOfCurrentGoodManufacturingPractices",
    "e": "e:0000353278",
    "u": "nvo:action",
    "p": "2017-01-01/2018-01-01"
   }
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84Ni9mcmFnOjI1MWM2ODQ0MDU1MDRlMWI4NGYzNzNiYTFjOTMxNDRlL3RleHRyZWdpb246MjUxYzY4NDQwNTUwNGUxYjg0ZjM3M2JhMWM5MzE0NGVfMjc0ODc3OTA3MjM5Mg_f8ec8701-681b-4955-ab28-af83ee27e0c2": {
   "v": "(ixTransformValueError)",
   "a": {
    "c": "sasb:ProductRecalls",
    "e": "e:0000353278",
    "u": "nvo:recall",
    "p": "2019-01-01/2020-01-01"
   },
   "f": "ixt-sec:numwordsen"
  },
  "id3VybDovL2RvY3MudjEvZG9jOjNmYWY3MmFjZGJkZTQ3MGQ4NmMyZmI5ZjA3NmRkOGRiL3NlYzozZmFmNzJhY2RiZGU0NzBkODZjMmZiOWYwNzZkZDhkYl84Ni9mcmFnOjI1MWM2ODQ0MDU1MDRlMWI4NGYzNzNiYTFjOTMxNDRlL3RleHRyZWdpb246MjUxYzY4NDQwNTUwNGUxYjg0ZjM3M2JhMWM5MzE0NGVfMjc0ODc3OTA3MjQwMQ_b2f5e2fd-b380-46a4-90c5-ff575b2b8edb": {
   "v": "(ixTransformValueError)",
   "a": {
    "c": "sasb:ProductRecalls",
    "e": "e:0000353278",
    "u": "nvo:recall",
    "p": "2018-01-01/2019-01-01"
   },
   "f": "ixt-sec:numwordsen"
  }
 },
 "prefixes": {
  "sasb": "http://www.sasb.org/xbrl/taxonomy/cor",
  "e": "http://www.sec.gov/CIK",
  "nvo": "http://novonordisk.com/20201207",
  "xbrli": "http://www.xbrl.org/2003/instance"
 },
 "roles": {
  "std": "http://www.xbrl.org/2003/role/label",
  "doc": "http://www.xbrl.org/2003/role/documentation",
  "calc": "http://www.xbrl.org/2003/arcrole/summation-item",
  "pres": "http://www.xbrl.org/2003/arcrole/parent-child",
  "w-n": "http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower",
  "ns0": "http://www.xbrl.org/2003/role/terseLabel",
  "ns1": "http://www.xbrl.org/2003/role/verboseLabel"
 },
 "rels": {}
}</script><!--END IXBRL VIEWER EXTENSIONS--></body></html>